Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo- and active-controlled trial of fluocinolone acetonide/hydroquinone/tretinoin cream for moderate to severe facial melasma
CTR20244786Phase 3Active
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tretinoin in melasma (3 arms), sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Primary endpoint: Clinical equivalence between test cream and reference formulation at Week 8. Started Jul 2025; status: active.
02
Drugs
tretinoin
03
Conditions
melasma
Beyond the preview
Go deeper on CTR20244786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244786.